---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-010098"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:01:12.428126+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunocore FY2023 KIMMTRAK sales $238.7M; launches PRAME Phase 3 with BMS

## Summary
- Q4 2023 KIMMTRAK net sales $67.6M; full year $238.7M (+12% YoY). US $169.8M, Europe $67.6M.
- Net loss FY2023 $55.3M ($1.13 loss per share) vs $52.5M in 2022. R&D $163.5M, SG&A $144.5M.
- Cash $442.6M at Dec 31; raised $389.3M net in Feb 2024 via 2.5% convertible notes due 2030.
- Entered collaboration with BMS for Phase 3 PRISM-MEL301 trial of IMC-F106C + nivolumab in 1L advanced melanoma; first patient Q1 2024.
- Multiple PRAME data readouts in 2024: cutaneous melanoma (Q2), ovarian (Q3), NSCLC (Q4). KIMMTRAK now in 12 launched countries.

## SEC filing metadata
- accession: 0001140361-24-010098
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124010098/0001140361-24-010098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124010098/ef20022689_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-010098
- JSON: https://secwatch.observer/filing/0001140361-24-010098.json
- Plain text: https://secwatch.observer/filing/0001140361-24-010098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.